Severity
Critical
FDA Drug recall · Reported July 19, 2023
Defective container: empty inhaler and leakage observed through the inhaler valve due to partially missing bottom seat (gasket).
Cipla USA, Inc. recalled Albuterol Sulfate Inhalation Aerosol, 90 mcg, 200 Metered Inhalation, net content 6.7 g c… - a critical-severity action.
Albuterol Sulfate Inhalation Aerosol, 90 mcg, 200 Metered Inhalation, net content 6.7 g c… was recalled by Cipla USA, Inc. in July 19, 2023. Reason: Defective container: empty inhaler and leakage observed through the inhaler valve due to partially missing bo…. Check the official notice for the remedy. Verify recall #D-0938-2023 with the FDA Drug before acting.
The recall
Cipla USA, Inc. issued this critical-severity FDA Drug recall-Defective container: empty inhaler and leakage observed through the inhaler valve due to partially missing bo….
Sourced from official FDA Drug enforcement records. Verify recall #D-0938-2023 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0938-2023) was formally reported on July 19, 2023, with the manufacturer initiating the action on June 27, 2023. It is classified under Critical severity (Class I), with a current status of Terminated. Cipla USA, Inc. is listed as the recalling firm, operating out of Warren, NJ. Federal records list the affected scope as 278,538 canisters.
The documented reason for this recall is: Defective container: empty inhaler and leakage observed through the inhaler valve due to partially missing bottom seat (gasket). Distribution data in the federal record shows the product reached: Nationwide in the US. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified high severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Critical
Affected scope
278,538 canisters
Related Recalls
6
5 from same agency
Albuterol Sulfate Inhalation Aerosol, 90 mcg, 200 Metered Inhalation, net content 6.7 g canister packaged in a box, Rx only, Manufactured by: Cipla Ltd, Indore SE Z, Pithampur, India, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ, 07059, NDC 69097-142-60
Defective container: empty inhaler and leakage observed through the inhaler valve due to partially missing bottom seat (gasket).
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Critical (Class I) |
| Status | Terminated |
| Recall number | D-0938-2023 |
| Date reported | July 19, 2023 |
| Date initiated | June 27, 2023 |
| Recalling firm | Cipla USA, Inc. |
| Firm location | Warren, NJ |
| Affected scope | 278,538 canisters |
| Distribution | Nationwide in the US |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported July 19, 2023. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.